The role of conservative surgery in malignant ovarian germ cell tumors. Malignant ovarian germ cell tumors (MOGCTs) represent approximately 5% of all ovarian malignancies and occur primarily in young women. They are diagnosed at stage I in 50 to 70% of cases and show survival rates up to 90% in early MOGCTs and up to 75% in advanced stages. This success is due to a mul-timodality treatment with primary surgery followed by platinum-based chemotherapy introduced since the 1980s. The aim of this study was to review current management and prognosis of patients with MOGCTs underwent conservative surgery. In stage I MOCGTs unilateral salpingo-oophorec-tomy and adjuvant chemotherapy are considered the standard treatment, except for stage IA dysgermino-ma and stage I immature teratoma in which surgery alone is the treatment of choice. Standard treatment for patients with stage II-IV MOGCT is cytoreduction followed by BEP (bleomycin, etoposide, platinum) chemotherapy. In advanced MOGCTs, preservation of fertility is also advised, considering that approximately 80% of patients will be long-term survivors, even if they have residual disease after cytoreductive surgery. In patients undergoing fertility-sparing surgery the number of pregnancies carried to term is high and adverse effects are not reported in the offspring. In conclusion, MOGCTs are rare malignancies that mainly affect young women and prognosis is excellent, so conservative surgery of MOGCTs has to be considered the gold standard.
|Translated title of the contribution||The role of conservative surgery in malignant ovarian germ cell tumors|
|Number of pages||8|
|Journal||Italian Journal of Gynaecology and Obstetrics|
|Publication status||Published - 2013|
ASJC Scopus subject areas
- Obstetrics and Gynaecology